Premier Dental Products Co. Initiates Class III Recall of Ferric Subsulfate Solution Due to Labeling Error
Premier Dental Products Company has initiated a voluntary Class III recall for 573 cartons of its Monsel's, Ferric Subsulfate Solution due to an incorrect expiration date on the vial. This event underscores critical labeling compliance requirements for pharmaceutical and medical device manufacturers. Procurement and regulatory teams must ensure robust quality control to mitigate supply chain disruptions and patient safety risks.
FDA Class III Recall: Premier Dental's Ferric Subsulfate Labeling Non-Compliance
Premier Dental Products Company, based in Plymouth Meeting, Pennsylvania, has initiated a voluntary Class III recall for 573 cartons of its Monsel's, Ferric Subsulfate Solution. This action, identified as recall number D-0490-2026, stems from a critical labeling error where the expiration date on the individual 8 mL vials was printed incorrectly. Specifically, the date appeared as '2709114' instead of the correct '270914', which corresponds to September 14, 2027. While the outer carton of the 12-bottle saleable unit correctly displayed the expiration date, the discrepancy on the primary container poses a direct compliance risk. For procurement directors and regulatory affairs heads, this incident highlights the absolute necessity of stringent quality control at every stage of the packaging process. An incorrect expiration date, even if seemingly minor and limited to the vial, can lead to dispensing errors, patient confusion, and potential administration of expired product, thereby compromising patient safety. The nationwide distribution pattern within the United States for this lot (640911253) means that a significant number of dental and medical practices could be impacted. Companies relying on Premier Dental Products Company for Ferric Subsulfate must immediately verify their inventory for affected NDC 48783-112-08 units and implement protocols for managing recalled products efficiently to mitigate operational disruption and maintain regulatory compliance.
Premier Dental Products Company: Facility and Product Overview
Premier Dental Products Company operates from its facility at 1710 Romano Drive, Plymouth Meeting, PA 19462-2822, United States. This site is responsible for the manufacturing and distribution of Monsel's, Ferric Subsulfate Solution, a human prescription drug classified for topical use. Ferric Subsulfate (UNII: 3QJ8WS6V8H) is a widely used hemostatic agent, particularly in dental and dermatological procedures, making its consistent and compliant supply critical for healthcare providers. The product, packaged in 8 mL bottles with NDC 48783-112-08, is distributed nationwide across the United States. For supply chain VPs and business development executives, this recall underscores the importance of understanding the manufacturing footprint and quality systems of key suppliers. While the specific capacity or market share of Premier Dental Products Company for Ferric Subsulfate is not detailed, any disruption from a primary US-based manufacturer can have ripple effects across the domestic supply chain. Ensuring that suppliers like Premier Dental Products Company have robust, verifiable quality management systems in place, particularly concerning labeling accuracy, is paramount to maintaining uninterrupted supply and avoiding costly product returns or regulatory penalties.
Supply Chain Exposure: Implications for Ferric Subsulfate Buyers
The voluntary recall of Premier Dental Products Company's Ferric Subsulfate Solution directly impacts procurement teams and downstream formulators across the United States. With 573 cartons of lot 640911253 distributed nationwide, any entity that has purchased or stocked this specific product is now exposed to potential operational and compliance challenges. While the Class III classification suggests a low probability of adverse health consequences, the regulatory expectation is that all affected product is identified and removed from circulation. This requires immediate action from distributors, pharmacies, and healthcare facilities that may have received the product. For procurement directors, this means initiating immediate internal audits of inventory to identify affected lots of NDC 48783-112-08. Regulatory affairs heads must ensure that internal procedures for recall management are efficient and fully compliant with FDA guidelines, including proper segregation, documentation, and return of affected units. Business development executives should assess the reputational impact on their own organizations if they are found to have distributed non-compliant products. This incident serves as a clear reminder that meticulous inbound quality checks are not merely good practice but a critical defense against regulatory exposure and potential supply chain disruption.
Alternative Suppliers: Mitigating Ferric Subsulfate Supply Risk
Given the recall of Premier Dental Products Company's Ferric Subsulfate Solution, procurement teams should proactively review their supplier diversification strategies for this critical hemostatic agent. While the current recall is Class III and firm-initiated, any disruption from a primary supplier necessitates a robust contingency plan. Companies should identify and qualify secondary and tertiary sources for Ferric Subsulfate to build resilience against future supply chain vulnerabilities, whether due to quality issues, manufacturing delays, or other unforeseen events. For supply chain VPs, this involves a comprehensive assessment of the global market for Ferric Subsulfate, identifying manufacturers with strong regulatory compliance records and reliable supply capabilities. Geographic diversity among suppliers can significantly reduce risk. Qualification timelines for new suppliers, including audits and analytical testing, can be extensive, often spanning several months. Therefore, initiating this process proactively is crucial. Regulatory affairs teams must ensure that any alternative supplier's product meets all necessary specifications and regulatory requirements for the intended market, preventing future compliance issues and ensuring continuity of essential medical supplies.
Broader Regulatory Landscape: Emphasizing Labeling and Quality Control
The Premier Dental Products Company recall, while specific to a labeling error, occurs within a broader regulatory environment characterized by heightened FDA scrutiny on pharmaceutical and medical device quality. Recent parallel events, such as FDA Class II recalls for sterility assurance deficiencies involving Essential Wellness Pharma's Progesterone Injection and Spectra Medical Devices' Lidocaine HCl Injection, alongside metallic contamination issues faced by Guardian Drug Co. Inc. for Calcium Carbonate Antacids, underscore a pervasive focus on manufacturing quality and data integrity across the industry. Although these specific incidents are unrelated to Premier Dental, they collectively signal the FDA's unwavering commitment to enforcing Good Manufacturing Practices (GMP). For senior decision-makers, this trend means that even seemingly minor deviations, like an incorrect expiration date, are viewed through the lens of overall quality system robustness. Regulatory affairs heads must recognize that such errors can trigger deeper investigations into a company's quality management systems. Business development executives should factor this stringent regulatory climate into their risk assessments for new partnerships and product launches. Investing in robust Quality Management Systems (QMS), comprehensive employee training, and advanced automation for labeling and packaging processes is no longer merely an operational advantage but a fundamental requirement for maintaining market access and avoiding costly regulatory actions.
Remediation and Future Compliance Outlook for Premier Dental
Following this voluntary Class III recall, Premier Dental Products Company is expected to implement comprehensive corrective and preventive actions (CAPA) to address the root cause of the labeling error on its Monsel's, Ferric Subsulfate Solution. As a firm-initiated action, the company has taken responsibility for identifying and addressing the issue. However, the FDA will closely monitor the effectiveness of these CAPA measures. This typically involves a thorough investigation into the printing and quality control processes, identification of human or systemic errors, and implementation of controls to prevent recurrence. For regulatory affairs and quality assurance teams, this means ensuring that Premier Dental's remediation plan is not only documented but demonstrably effective. Failure to adequately address the underlying issues could escalate future regulatory actions, potentially leading to more severe classifications of recalls, official FDA Warning Letters, or even import alerts if international distribution were involved. Procurement directors should maintain open communication with Premier Dental Products Company to understand their remediation progress and ensure confidence in future product quality. The ability of Premier Dental to demonstrate sustained compliance will be crucial for maintaining its market position and ensuring the continued supply of Ferric Subsulfate Solution to its customers nationwide.